Leveraging AI for Drug Discovery: Analyzing Collaborations Incentives Among Biotech Companies

Applications of Game Theory to Business,
City University of Hong Kong

Cesare Bergossi

November 2023

Abstract

The incorporation of Artificial Intelligence has heavily impacted the research approach in the rapidly evolving landscape of pharmaceutical innovation, leading to a new era of drug discovery. This study explores the deep implications of AI-driven drug discovery collaborations within the biotechnology sector, in a scenario where companies strive to maintain a subtle balance between cooperation and the pursuit of their own interests. Analyzing the strategic dynamics between biotech firms and AI-oriented organizations, this research aims to shed light on the ways in which these collaborations impact medical innovation and optimize resource allocation, shaping the future of pharmaceutical development.

Introduction

Drug research and development have undergone a substantial shift, thanks to AI-driven techniques in the biotech landscape. Artificial Intelligence is playing a key role in this age of cutting-edge technology, changing the way that the pharmaceutical industry approaches drug discovery through conventional methods. Beyond simple automation, AI is becoming a strategic collaborator that influences the dynamic interactions between biotech firms and technology-oriented institutions.

The precarious balance between collaboration and individual goals becomes a focus point as AI gets more and more present in drug research procedures. This study explores the strategic dynamics of AI-driven partnerships between biotech companies, revealing the incentives that either drive these kinds of alliances or induce them to pursue their own R&D path to optimize resource allocation.

The following sections examine the multiple applications of AI in drug discovery, from its central function in drug design and customized medicine strategies, to its capability of efficiently reducing time spent on research. Examining collaborative initiatives through the lens of game theory, we analyze the trade-off between cooperation and competition, uncovering the complex choices that biotech firms and AI-oriented organizations must make. Addressing obstacles to effective collaboration, we expose the challenges and ethical considerations that require careful maneuvering in this constantly changing environment.

The Role of AI in Drug Discovery

Artificial Intelligence is playing a pivotal role in drug discovery, historically one of the most complicated areas of research, reshaping the conventional paradigms and propelling the industry into a new era characterized by unprecedented efficiency and innovation.

At first, these powerful computational tools have been employed focusing on small molecules, an extremely important research area which constituted about 90% of global pharmaceutical sales in 2021. AI was in fact used to predict interactions with small molecules' targets and optimize their effectiveness.

However, thanks to major investments coming from pharma and venture capital, companies have started applying AI to tougher challenges: large molecules such as antibodies, proteins, gene therapies, and RNA-based treatments. These are predicted to be the biopharma industry's pipeline going forward, and already accounted for 40% of new drug approvals in 2022.

- **AI-Powered Drug Design**

  AI-driven techniques, among which cutting-edge tools like AlphaFold2 and RoseTTAFold, showcase a methodological shift in predicting protein structures, a cornerstone of drug design. These tools accurately forecast the intricate features of three-dimensional protein structures, and can eliminate years of laboratory work to determine the structure of a single protein, now achievable in as little as 10 minutes.

- **Time Efficiency in AI-Driven Drug Discovery**

  The impact of AI is most expressed in the capacity of significantly diminishing the time and cost traditionally associated with discovering new drugs. Through sophisticated algorithms and predictive models, AI quickly identifies potential drug candidates, which not only benefits pharmaceutical companies, but also assists with the delivery of life-changing medications to patients in much shorter times.

- **Personalized Medicine Strategies**

  Crucial has been the employment of generative AI engines, which combined with the search for immunotherapy treatments has the potential to boost the development processes of personalised medicines. These regimens are specifically tailored to each patient, built by identifying TCR sequences with the highest chance of working against a given patient's particular cells.

Collaborations between Pharma and AI-oriented Organizations

Due to these multifaceted benefits and drastic changes dictated by AI in the biotech sector, an increasing number of opportunities are emerging for pharmaceutical firms, making the scenario incredibly more competitive, yet tremendously boosting their growth and income potential.

As AI's capabilities are discovered, these companies progressively recognize the need for strategic collaborations with AI-oriented entities. The need to enhance drug development and target identification, while toning down the complexities of clinical trials is what fuels these collaborations.

This is especially crucial for small biotech companies. Most of them typically lack expertise in data analytics, and possess a limited amount of data to analyze, hence making them hardly able to generate relevant information to drive their business decisions. Larger companies, on the other hand, hold a data monopoly, placing smaller, more innovative ones in a challenging position to catch the right information for the right context. This accentuates the need for collaborations, serving as a strategic bridge between the limited data capacities of smaller biotech firms and the extensive resources possessed by larger enterprises.

Among these collaborations between biotech firms and established pharma, notable examples include partnerships like BenevolentAI and AstraZeneca, Insilico Medicine and Sanofi, and Exscientia and Bayer. Conversely, several pharmaceutical companies, such as GSK, Novartis, and Roche, are establishing their own in-house AI capabilities.

According to research from GlobalData, the number of partnerships for AI-based drug discovery initiated by major pharmaceutical companies was only four in 2015. By 2020, this number had surged to 27, marking a remarkable 575% increase. This upward trend indicates a growing recognition of the potential benefits derived from merging deep, quality data and expertise with increasingly sophisticated AI capabilities, presenting a potential to truly shift the future of medicine.

Trade-off between Collaboration and Competition

While successful partnerships have proven mutually beneficial, not every product and activity are the result of fruitful collaboration. Executives face a challenging decision-making process, where even collaborations with the best of intentions can falter, especially in the public sector.

Let us analyze this scenario through a game theoretical perspective. We can envision a pharmaceutical firm and an AI-driven organization as players in a Prisoner's Dilemma game during a certain time

period. This specific model helps us understand why competing might be preferred to cooperating in a single stage game. Simplifying the interactions to three possibilities reveals strategic choices:

- Mutual Cooperation: Both firms share knowledge and expertise, achieving a certain payoff (a).
- Mutual Competition: Both work independently, utilizing limited knowledge, only managing to achieve a lower payoff (b).
- Asymmetric Collaboration: Suppose one firm opts for collaboration, sharing its data or IT techniques publicly. The non-collaborating firm has all the essential tools for independent work, leading to relevant scientific discoveries and achieving the highest payoff (c). The collaborating firm, left on its own, obtains a smaller market share and achieves the lowest payoff (d).

	Collaborate	Compete
Collaborate	(a, a)	(d, c)
Compete	(c, d)	(b, b)

In this setting ($c > a > b > d$), the unique Nash Equilibrium is the scenario where both firms compete (b, b), as none of the two has any incentive to deviate, despite the potential for mutual benefit (a, a). This highlights the challenge of aligning individual interests with collective gains.

Adding complexity, real-world scenarios typically involve repeated strategic interactions over time. This changes the outcome of this decision framework and encourages the consideration of strategies like the Grim Trigger. Firms attempt to cooperate and instantly switch back to competing as soon as the other party decides to stop collaborating. Compared to the single stage game, companies are now influenced by a discount factor and by the duration of collaboration: strategic sharing of resources becomes incentivized in long-term collaborations, offering a counterbalance to the general tendency to compete and safeguard assets. The variability in discount factors depends on the company's trust in the cooperation, hence each collaboration necessitates individualized analysis.

In the AI-powered drug discovery landscape, a notable trend emerges as pharmaceutical firms increasingly opt for internal development over external collaboration. This shift fuels a demand of profiles bridging computer science and biology, leading to a proper bioinformatics revolution. The logic behind this internalization reflects a careful evaluation of factors like the duration of collaboration, discount rates, and the dynamic nature of pharmaceutical innovation.

Concluding Remarks: Future Trends, Challenges and Ethical Considerations

The landscape of AI-driven large-molecule drug discovery is experiencing an unprecedented surge, marked by the emergence of over 80 companies in the last five years. This rapid growth emphasizes the industry's dynamism, driven by technological advancements and substantial funding. Investment in this sector has reached remarkable levels, hitting $3.9 billion in 2021, with a huge portion coming from venture capital. This is further proven by the successful public offerings of companies like AbCellera and Absci, dedicated to antibody and biologics discovery, and by important strategic collaborations, like the acquisition of Prescient Design, an AI-powered player in antibody discovery, by Genentech, or the cooperation between Lilly and AbCellera on COVID research.

These trends do however come with challenges to face. Critical steps include the integration of AI models into research processes, bridging the gap between data scientists and domain experts, and managing expectations around the capabilities of AI to maintain credibility and trust.

Moreover, success strongly depends on high-quality, integrated data, leading to issues of data silos, interoperability and accuracy. This also opens to ethical concerns, as AI-driven drug discovery heavily relies on personal data. Ensuring the privacy and security of patient information, as well as transparent methods, is crucial. In addition, bias in training data may lead to treatments that are less effective for specific groups, contributing to healthcare disparities.

This evolution is not only about introducing the right technological tools, but rather about reshaping an entire industry.

References

[1] **Licholai, Greg** (2023) "AI Is Game Changer For Toughest Areas Of Drug Discovery", *Forbes*

[2] **Marr, Bernard** (2023) "Breakthrough In Cancer Treatment: The Role Of Generative AI In Drug Development", *Forbes*

[3] **Nouri, Steve** (2023) "Generative AI Drugs Are Coming", *Forbes*

[4] **Innoplexus** "Leveraging AI for Drug Discovery in early stage Biotech Companies", *Innoplexus Blog*